eMedicine Specialties > Neurology > Seizures and Epilepsy

Epilepsia Partialis Continua

Author: Claude G Wasterlain, MD, Chair, Department of Neurology, VA Greater Los Angeles Health Care System; Distinguished Professor and Vice-Chair, Department of Neurology, University of California, Los Angeles, David Geffen School of Medicine
Coauthor(s): Leo L Chen, MD, Staff Physician, Department of Neurology, University of California at Los Angeles
Contributor Information and Disclosures

Updated: Jul 15, 2009

Introduction

In 1895, Kojewnikoff described a unique type of prolonged seizure, which he named epilepsia partialis continua (EPC). Since then, this name has been ascribed to various nosological entities: EPC as a variation of jacksonian epilepsy, as a jacksonian status epilepticus, as myoclonus epilepsy, as continuous localized myoclonia, or as an extrapyramidal syndrome.1

This phenomenon can be considered the status epilepticus equivalent of simple partial motor seizures. It manifests itself as focal motor clonic seizures without jacksonian march; seizures remain localized to the part of the body in which they originate; motor activity is often persistent, lasting for at least 60 minutes and often for hours, days, weeks, or even longer. Consciousness usually is preserved but postictal weakness is frequently evident.2,3 In the vast majority of cases, the seizures are of cortical origin; however, subcortical mechanisms also have been proposed.4 Antiepileptic drugs, with a few notable exceptions, do not seem to significantly alter the course of this condition.5 EPC can be an expression of a stable neurological lesion or a progressive disease, such as Rasmussen syndrome.6

Historical Perspective

Kojewnikoff7 , Bruns8 , Olowski9 , and Choroschko10 all reported a similar epileptic condition characterized by intermittent muscular twitching of a body part while consciousness is unaffected. To this condition, Kojewnikoff gave the name of epilepsia partialis continua (EPC). He claimed that its cause might be a tumor, an abscess, syphilis, edema, embolism, or a localized encephalitis. He postulated, without postmortem studies, that the seizures resulted from focal cortical encephalitis.11 This original description of EPC has been discussed by Spiller12 , Burr13 , and others.

During the period 1904-1907, Speilmeyer14 and Mills15 reported, under the name of jacksonian epilepsy, cases in which EPC may have been present. Since then, a number of clinical and pathologic studies have further defined the syndrome, its location, and its etiology.16 In 1966, Juul-Jensen and Denny-Brown4 defined, or rather, described, EPC as "clonic muscular twitching repeated at fairly regular short intervals in one part of the body for a period of days or weeks." They also differentiated it from myoclonus by characterizing the latter as "more rapid, lasting less than half a second, involving a variable number of muscles . . . at irregular intervals," but recognized the existence of transition forms, which are difficult to classify.

In 1972, Gastaut defined EPC as a subtype of somatomotor simple partial status epilepticus (SE), which was itself a form of elementary partial status epilepticus; this definition made the point that there are as many types of status epilepticus as there are types of seizures.17 Several subsequent reviews have used this definition.18

In 1977, Thomas et al defined EPC as "a partial somatomotor SE...for a minimum of one hour and recurring at intervals of no more than 10 seconds." They carefully described the features of EPC in 32 patients.16 EPC had a sudden onset in 17 of 25 patients; its duration varied from 4 hours to 18 years. Movement frequency was 0.5-10 Hz, and the duration varied from 25-600 milliseconds, with twitches often recurring every 2-3 seconds. An EEG spike or sharp wave preceded the movement in 9 of 12 patients, and all 5 corticographies revealed a cortical origin. Seventeen of 25 patients had a poor response or no response to anticonvulsants, and 6 of the 7 responders suffered from acute brain lesions; the therapeutic success could have been coincidental. Interestingly, cortical excision failed to stop the seizures in 4 of 5 patients.

In 1985, Obeso defined EPC as spontaneous regular or irregular clonic muscle twitching of cerebral cortical origin, confined to one part of the body and continuing for a period of hours, days, or even weeks.19 The addition of "irregular" to the description recognizes the fact that the interval between motor twitches can vary but, in the author's view, makes a clear distinction from myoclonus impossible. Cockerell et al in 1996 and Shorvon in 1994 defined EPC as "a syndrome of continuous focal jerking of a body part, . . . occurring over hours, days, or even years" and restricted the definition to jerks of cortical origin; they proposed the name "myoclonica continua" for jerks of subcortical origin.20,21 While this distinction is attractive in principle, in practice localizing the exact origin of the seizures is often difficult, and clinical activity indistinguishable from EPC has been associated with subcortical pathology (eg, multiple sclerosis).

Wilson and MacBride in 192511 , Hess and Sethi in 199022 , and Biraben and Chauvel in 1998 restricted EPC to local and elementary motor signs, regardless of whether it was associated with spreading seizures at times.23 Indeed, while the localized nature of EPC is one of its most striking features, occasional spread is seen in otherwise typical cases, and using it as an exclusion criterion is not warranted.

Definition

The author defines epilepsia partialis continua as a form of partial status epilepticus with simple motor manifestations that are maintained for over 1 hour, with clonic activity restricted to one body part and recurring at fairly regular intervals. The following modifying factors apply:

  • Motor activity often is modified by sensory stimuli.
  • Frequency is usually 0.1-6 Hz.
  • An occurrence of EPC can continue for long periods of time (sometimes years) without spreading, although spread can occur at times.
  • EPC often is associated with postictal or interictal weakness.
  • Clinical evolution distinguishes 2 forms (ie, Bancaud type 1, Bancaud type 2): type 1 is usually symptomatic of a focal brain lesion, and the prognosis is the same as that of the associated lesion; type 2 is associated with progressive, idiopathic, neurological deterioration, usually in the form of Rasmussen encephalitis (see Bancaud's classification in Clinical Presentation).

Epidemiology

Since the first description by Kojewnikoff, a number of isolated case reports and small case series have elucidated this syndrome further; unfortunately, however, few epidemiologic studies have been performed. The incidence of EPC is slightly higher in males than in females.20,4,16 Cockerell et al20 estimated the prevalence of EPC at less than 1 per million, based on 36 cases reported in the United Kingdom over a 1-year period, 10 of the cases being new.

A retrospective review by Sinha observed 76 patients with EPC at a tertiary care center in South India over the course of 14 years. The patient characteristics were as follows: Male-to-female ratio, 46:30; mean age, 30.2+/-23.4 years; and median age, 26 years. About 5-6 cases of EPC were admitted each year in this major referral center that has catered to about 3000-4000 inpatients per year for the past decade.24

Etiology

Clinical and pathologic studies identified various causes of EPC (summarized in Causes below). This long list reflects the diverse nature of the pathological processes that cause focal neocortical seizures. Nothing about these processes is specific, and the unique clinical features of EPC are likely to reflect its anatomical location rather than its etiology. The limbic system, which is involved heavily in processes such as memory and emotion, is designed to spread excitation widely and to modulate excitability of many brain regions; perhaps, as a result of this organization, seizures of limbic origin spread widely and rapidly.

By contrast, neocortex, which is involved in sensory, motor, and cognitive responses, is endowed with powerful lateral inhibition, which probably is designed to keep responses precisely localized. This may be the reason that EPC can go on for a long period of time while remaining precisely localized to a small group of muscles and a small cortical domain. An experimental counterpart of that dichotomy is seen in the different expressions of neocortical versus limbic kindling. Limbic kindling rapidly disseminates seizures across the brain, while seizures induced by neocortex remain localized and spread widely only after gaining access to limbic circuits.

Causes
  • Cerebral neoplasia
    • Metastasis25
    • Astrocytoma25
    • Oligodendroglioma25
    • Carcinomatosis cerebri25
    • Hemangioma18
    • Lymphoma18
    • Meningioma20
  • Cortical dysplasias
    • Cortical dysplasia26,27,28
    • Hemimegalencephaly23
    • Tuberous sclerosis23
    • Linear sebaceous nevus syndrome23
    • Sturge-Weber syndrome23
  • Infectious or parasitic
    • Abscess25
    • Tuberculoma4
    • Gumma25
    • Russian spring-summer encephalitis25
    • Subacute measles encephalitis23
    • Human immunodeficiency virus29
    • Progressive multifocal leukoencephalopathy30
    • Creutzfeldt-Jakob disease20
    • Viral encephalitis or meningo-encephalitis25
    • Cryptococcal meningitis31
    • Anti-Hu-associated paraneoplastic encephalitis32
    • Cysticercosis25
    • Granulomatous diseases25
    • Pertussis infection33
  • Vascular lesions
    • Arteriosclerotic cerebrovascular disease25
    • Embolic or postthrombotic ischemic infarction25
    • Cortical venous thrombosis25
    • Cerebral hemorrhage25
    • Systemic lupus erythematosus23
    • Sjögren syndrome34
    • Arteriovenous malformation23
    • Carotid hypoplasia35
  • Traumatic lesions
    • Acute head trauma36
    • Posttraumatic cyst25
    • Subdural hematoma25
    • Intracerebral hematoma25
    • Epidural hematoma25
  • Drug induced
    • Penicillin25
    • Azlocillin37
    • Cefotaxime37
    • Metrizamide38
  • Metabolic
    • Diabetic ketoacidosis39
    • Nonketotic hyperglycemia40
    • Hepatic encephalopathy5,41
    • Uremic encephalopathy5
    • Hyponatremia5
  • Idiopathic
    • Rasmussen chronic encephalitis23,25
    • Autoimmune
      • Multiple sclerosis42
      • Anti-GluR3 or Anti-NMDA-GluR-Epsilon2 antibodies
    • Genetic
      • Alpers disease
      • Kufs disease43
      • Leigh syndrome and cytochrome C oxidase deficiency44
      • Nicotinamide adenine dinucleotide (NADH) coenzyme Q reductase deficiency45
      • Mitochondrial cytopathies including mitochondrial encephalopathy with lactic acidosis and stroke (MELAS)46

Pathophysiology

Historical studies

In 1885, Kojewnikoff postulated that myoclonus and seizures arose from the cerebral cortex in association with localized encephalitis.7 This brilliant insight contrasted with the then current view that somewhat similar clinical entities, such as Friedreich paramyoclonus multiplex and familial progressive myoclonic epilepsy of Unverricht, resulted from hyperexcitability of the anterior horn cells47 , and it has been proven right in the overwhelming majority of cases of EPC. In 1922, Souques48 considered that dysfunction of the motor cortex was the cause of focal motor seizures but that localized myoclonias must be of subcortical origin. The first EEG study of myoclonus with epilepsy was performed by Grinker et al49 in 1938. They demonstrated a temporal correlation between frontal polyspikes and waves and myoclonic jerks in the periphery.

In 1947, Dawson50,51 showed that the motor jerks were preceded by fast (30 Hz) discharges in the contralateral motor cortex. The EEG discharge had a consistent waveform, beginning with a positive wave immediately followed by a negative shift on which a train of spikes was superimposed. When neither the negative shift nor the spike train occurred, no myoclonic jerking was observed.

Dawson also recorded scalp somatosensory-evoked potentials (SSEP) for the first time in response to electrical stimulation of the nerve trunk. Their maximal amplitude was located near the midline for the lower limb and 6-8 cm lateral to the midline for the upper limb. He concluded that these evoked potentials represented exaggerated responses of the underlying cortex to peripheral stimuli, and that hyperexcitability of motor cortex, rather than increase of afferent volley to the primary somatosensory cortex via subcortical mechanisms, would account for the precentral site of projection.

Kugelberg and Wieden reported a case of EPC and remarked upon the constant relationship, with a 27- to 34-millisecond latency, between myoclonic jerking of the right foot and the focal EEG spikes in the central areas, maximum on the left side near the midline. In this patient, excision of the motor cortex was followed by complete remission of the seizures.52

Physiology

The unequivocal cortical origin of EPC appears to be substantiated in man by clinical, electrophysiological, and neurosurgical evidence. In addition, an epileptogenic lesion of the central cortex can provoke the appearance of this phenomenon in monkeys.53 Since surround inhibition may limit seizure spread more effectively in motor neocortex than in any other area because of the tight afferent-efferent relationships, which support the activation of long-loop reflexes, EPC may be a unique expression of cortical organization.54,55 However, note that seizures sometimes can be driven from distant or even subcortical sites.56

Metabolism

The EPC focus (1) is hypermetabolic as shown by 2-deoxyglucose positron emission tomography (PET); (2) is hyperactive as seen as by magnetoencephalogram (MEG) studies; and (3) shows increased blood flow in single-photon emission computed tomography (SPECT) studies.23

Synaptic mechanisms

Synaptic mechanisms have been studied only in self-sustaining status epilepticus, not in EPC. The author now suspects that self-sustaining status epilepticus is initiated by failure of GABAergic inhibition but is maintained by widespread potentiation of excitatory (especially N -methyl-D-aspartate [NMDA]) synapses; therefore, established self-sustaining status epilepticus becomes resistant to all agents except NMDA antagonists.57 The author could speculate on a similar mechanism in EPC, in which the focus would be characterized by long-term potentiation of glutamate receptors and desensitization of GABA receptors, while GABAergic inhibition would be preserved in the surround.

One patient suffering from a cerebral arteriovenous malformation, who developed EPC of several weeks' duration resistant to phenytoin, carbamazepine, valproate, benzodiazepines, gabapentin, phenobarbital, and primidone, did respond to felbamate, a blocker of NMDA receptors. Further studies will elucidate whether this isolated success was coincidental. Another case of successful treatment with felbamate also has been reported.58

Clinical Presentation

Clonic activity can involve any muscle group (see Topographic distribution) and is most common in the upper extremities. Although it is typically invariant and remains localized to a single muscle group in most patients, it may be accompanied by jacksonian spread of the seizure, which may even lead to a complex partial or secondarily generalized seizure. This syndrome also may be accompanied by other neurological and psychopathological symptoms (see Neurological symptoms and Neuropsychological symptoms). Bancaud et al classified EPC into 2 groups (see Bancaud's classification). Both entities start with similar seizures, but type 2 proves to be intractable and progressive. Bancaud divided the clinical course of type 2 into 3 stages, which are as follows:53

  • The first stage features only simple partial motor or complex partial seizures, but EPC may occur.
  • In the second stage, EPC is seen in the setting of progressive neurological deficit and mental deterioration.
  • The third stage is characterized by arrest of deterioration and decrease or disappearance of seizures.
Topographic distribution (n=139, total 151)1
  • Head (n=24)
    • Mouth (9)
    • Face (11)
    • Periorbital muscle (2)
    • Soft palate (2)
    • Hypersalivation (1)
  • Upper extremities (n=60)
    • Thumb (4)
    • Finger (6)
    • Hand (24)
    • Arm (26)
  • Head and upper extremities (n=21)
  • Trunk (n=8)
    • Shoulder (4)
    • Breast (1)
    • Abdomen (3)
  • Lower extremities (n=22)
    • Big toe (2)
    • Leg (10)
    • Foot (10)
  • One side of the body (n=16)
Neurological symptoms (n=116, total 246)1
  • Motor deficit - 138 (56%)
    • Tetraparesis - 4 (4%)
    • Hemiparesis - 68 (28.3%)
    • Monoparesis - 33 (13.3%)
    • Oculomotor paresis - 2 (0.7%)
    • Facial paresis - 25 (10%)
    • Hypoglossal paresis - 5 (1.9%)
    • Soft-palate paresis - 1 (0.3%)
  • Sensory deficit - 52 (21%)
    • Hemihypoesthesia and hemianesthesia - 24 (9.7%)
    • Monohypoethesia and monoanesthesia - 11 (4.4%)
    • Deep sensation – 9 (3.6%)
    • Stereognosis - 8 (3.3%)
  • Conjugate deviation of the eyes - 3 (1%)
  • Anisocoria - 2 (1%)
  • Homonymous hemianopsia - 13 (5%)
  • Aphasia - 33 (14%)
    • Motor - 21 (8.8%)
    • Sensory - 6 (2.6%)
    • Amnestic - 6 (2.6%)
  • Apraxia - 2 (1%)
  • Alexia - 2 (2%)
Neuropsychological symptoms (n=41, total 59)1
  • Disturbance of consciousness - 21 (36%)
    • Somnolence - 11 (19%)
    • Stupor - 2 (3%)
    • Coma – 8 (14%)
  • State of confusion - 9 (15%)
  • Disorientation - 6 (10%)
  • Labile affect - 3 (5%)
  • Stupor - 3 (5%)
  • Dementia - 9 (15%)
  • Others - 8 (14%)
Bancaud's classification59
  • Type 1 (classic)
    • Rolandic fixed lesion
    • Neurological deficit
    • Preceding partial motor seizures
    • Following myoclonic jerks
    • Focal abnormalities on EEG
    • Nonprogressive course
    • Surgery usually effective
  • Type 2 (Rasmussen)
    • Normal development and history until seizure onset
    • Preceding partial motor seizures
    • Following myoclonic jerks
    • Abnormal EEG background with focal and diffuse paroxysmal abnormalities
    • Progressive course
    • Chronic encephalitis
  • Intractable epilepsy

Diagnostic Evaluation

Neurologic evaluation is essential in view of the variety of etiologies and associated illnesses. Magnetic resonance imaging (MRI) can point to the structural lesion of the cortex and/or white matter, and it also can follow the progression of atrophy in Bancaud type 2 EPC.23 In general, EEG has not been successful in determining the origin of EPC. In Rasmussen encephalitis, the EEG often shows significant lateralized slow-wave activity, and it may give evidence for other seizure types or projected abnormalities suggestive of widespread but lateralized disease. Frequently, lateralized asymmetric background slowing is noted.

Similar findings also can be seen with other etiologies, such as glial tumors. In the case of focal nonprogressive pathologies, such as chronic stroke, the background is rarely as abnormal or asymmetric. This point may help in differentiating a focal nonprogressive pathology from structural diseases with a coexistent metabolic encephalopathy, in which the background is often diffusely abnormal.

Evoked-potential techniques (especially SSEP) have been used to examine the physiological mechanisms and anatomical locations of EPC.5 Giant SSEPs are seen often and point to cortical hyperexcitability, which may be an essential mechanism of EPC. PET and SPECT are emerging as useful research tools in the evaluation of the metabolic effects of EPC, especially when CT and MRI findings are normal. PET studies are also likely to enhance understanding of the biochemical and metabolic features associated with the abnormal physiology, and, consequently, they may provide significant information not only for diagnosis but also for treatment of EPC.60

SPECT-MRI fusion has been reported by Matthews to be successfully used to identify epileptic focus in a patient with EPC.61 Burneo reported that ictal SPECT has also been useful in the presurgical evaluation of Rasmussen encephalitis.62

Prognosis

The long-term prognosis of EPC depends completely on its underlying cause. The early onset of EPC in a child is often, but not always, a manifestation of neurodegenerative disease or Rasmussen encephalitis, and these conditions often are associated with progressive neurological decline. In cases with adult-onset EPC, the underlying cause can be fixed (eg, cortical dysplasia, stable arteriovenous malformation), self-limiting (eg, trauma, stroke), or progressive (eg, tumor, carcinomatous meningitis); the prognosis depends on the underlying pathology.

Treatment

Treatment should focus on the underlying condition. Antiepileptic drugs (AEDs) must be tried to prevent the spread of EPC but, with a few notable exceptions, are unsuccessful in altering the course of EPC. Phenytoin or phenobarbital may be more effective than carbamazepine or valproate.23 Echenne reported a case of felbamate success in a patient with hemimegalencephaly and multiple types of seizures that responded poorly to AEDs.58

Oral corticosteroid therapy and immunosuppression may be of some benefit in rare cases.25 A correlation has been found between Rasmussen encephalitis and serum antibodies to the glutamate receptor subunits, GluR363 and NMDA-type GluR-Epsilon2.

Plasma exchange has been reported to have improved EPC significantly. Barrontini et al64 reported the use of gamma globulins, but to date few lasting benefits have been reported.

Transcranial magnetic stimulation has been reported to have lasting success in anecdotal cases and seems to deserve further evaluation.65,66  More recently, Rotenberg has reported patients with EPC who benefited from transient suppression of seizures by undergoing low-frequency transcranial magnetic stimulation.67

Nimodipine has been administered successfully in 2 cases of EPC following an acute cerebral event.68 Since cytomegalovirus has been implicated in the pathogenesis of Rasmussen syndrome, McLachlan et al69 used ganciclovir and reported that EPC was controlled in one patient with this syndrome. Intraventricular interferon alpha was reported to have completely controlled EPC in a patient with Rasmussen encephalitis.

Neurosurgical approaches, such as multiple subpial transections70 , may be used as a last resort. Hemispherectomy should be considered in refractory cases of Rasmussen encephalitis. Chronic electrical stimulation was used in 3 patients with EPC, resulting in a decrease in seizure frequency and paroxysmal discharges.

A case of successful treatment of facial myoclonus with botulinum toxin for symptomatic relief from EPC has been reported by Browner.71

Patient Education

For excellent patient education resources, visit eMedicine's Brain and Nervous System Center. Also, see eMedicine's patient education article Epilepsy.

Keywords

epilepsy, epilepsy treatment, epilepsy symptoms, simple partial status epilepticus, jacksonian status epilepticus, continuous localized myoclonia, somatomotor simple partial status epilepticus, EPC, myoclonus epilepsy

 
Acknowledgments

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author Guillermo Estrada, MD to the development and writing of this article.



More on Epilepsia Partialis Continua

References

References

  1. Lohler J, Peters UH. [Epilepsia partialis continua (Kozevnikov epilepsy)]. Fortschr Neurol Psychiatr Grenzgeb. Apr 1974;42(4):165-212. [Medline].

  2. Bancaud J, Bonis A, Trottier S. [Continuous partial epilepsy: syndrome and disease]. Rev Neurol (Paris). 1982;138(11):803-14. [Medline].

  3. Gastaut H. [Semeiology of myoclonus and analytic nosology of myoclonic syndromes]. Rev Neurol (Paris). Jul 1968;119(1):1-30. [Medline].

  4. Juul-Jensen P, Denny-Brown D. Epilepsia partialis continua. Arch Neurol. Dec 1966;15(6):563-78. [Medline].

  5. Shomer DL. Focal status epilepticus and epilepsia partialis continua in adults and children. Epilepsia. 1993;34(Suppl 1):S29-S36.

  6. Bancaud J, Bonis A, Talairach J. [Kojewnikow syndrome and somato-motor attacks (clinical, E.E.G., E.M.G. and S.E.E.G. study)]. Encephale. Sep-Oct 1970;59(5):391-438. [Medline].

  7. Kojewnikoff AY. Eine besondere Form von corticaler Epilepsie. Neurologie Zentralblatt. 1895;14:47-48.

  8. Bruns. Anastomische und klinische Demostrationen. Neurol ZentraIbI. 1895;14:47-48.

  9. Orlovskij SB. Ein Fall von epilepsia partialis continua. Medskoe Obozr Sprimona. 1825;43:210.

  10. Choroschko VK. Zur Differentialdiagnostik der Polyclonia epileptoides continua (Kozevnikov) Obozr Psikhiat Nevrol Eksp Psikhol 7. Nr 10. Zitiert nach Ref In Neurol Zbl. 1907;27, 279.

  11. Wilson G, Winkelman NW. Partial continuous epilepsy. Arch Neurol Psychiat. 1924;11:530-42.

  12. Spiller WG, Martin E. Epilepsia partialis continua occurring in cerebral syphilis. JAMA. (June 12) 1921;52.

  13. Burr CW. Continuous clonic spasm of the left A (epilepsia continua) caused by a tumor of the brain. Am J Med Sci. 1915;149:169.

  14. Spielmeyer W. Zur Symptomatologie der Grosshirnencephalitis, speziell uber eine epileptische form dieser Erkrankung. CentrtraIbI F Nervenh u Psychiat. 1904;27:371-383.

  15. Mills CK. Circumscribed haemorrhagic cortical encephalitis, with the report of a case in which the lesion was limited to the motorzone, the chief clinical manifestation Jacksonian epilepsy. Rev Neurol Psychiat. 1907;5:389.

  16. Thomas JE, Reagan TJ, Klass DW. Epilepsia partialis continua. A review of 32 cases. Arch Neurol. May 1977;34(5):266-75. [Medline].

  17. Gastaut H. Classification of status epilepticus In: Delgado-Escueta AV, Wasterlain CG, Treimann DM, Porter RJ, eds. Status Epilepticus. (Adv Neurol, vol 34). New York: Raven Press;1983:15-35.

  18. Schomer DL. Focal status epilepticus and epilepsia partialis continua in adults and children. [Review] [51 refs]. Epilepsia. 1993;34 Suppl 1:S:29-36.

  19. Obeso JA, Rothwell JC, Marsden CD. The spectrum of cortical myoclonus. From focal reflex jerks to spontaneous motor epilepsy. Brain. Mar 1985;108 ( Pt 1):193-24. [Medline].

  20. Cockerell OC, Rothwell J, Thompson PD, et al. Clinical and physiological features of epilepsia partialis continua. Cases ascertained in the UK. Brain. Apr 1996;119 ( Pt 2):393-407. [Medline].

  21. Shorvon S. Status Epilepticus: Its Clinical Features and Treatment in Children and Adults. Cambridge: Cambridge University Press;1994.

  22. Hess DC, Sethi KD. Epilepsia partialis continua in multiple sclerosis. Int J Neurosci. Jan 1990;50(1-2):109-11. [Medline].

  23. Biraben A, Chauvel P. Epilepsia partialis Continua. In: Engel J, Pedley TA, eds. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven Publishers;1998:2447-53.

  24. Sinha S, Satishchandra P. Epilepsia Partialis Continua over last 14 years: experience from a tertiary care center from south India. Epilepsy Res. Apr 2007;74(1):55-9. [Medline].

  25. Walker M, Shorvon S. Treatment of status epilepticus and serial seizures. In: The Treatment of Epilepsia. Blackwell Science Ltd;1996:280-2.

  26. Ferrer I, Pineda M, Tallada M, et al. Abnormal local-circuit neurons in epilepsia partialis continua associated with focal cortical dysplasia. Acta Neuropathol (Berl). 1992;83(6):647-52. [Medline].

  27. Kuzniecky R, Powers R. Epilepsia partialis continua due to cortical dysplasia. J Child Neurol. Oct 1993;8(4):386-8. [Medline].

  28. Norborg C, Sourander P, Silfvenius H, et al. Mild cortical dysplasia in patient with intractable partial seizures: A histological study. In: Wolf P, Dam M, Janz D, Dreifuss F, eds. Advances in Epileptology: the XVIth Epilepsy International Symposium. New York:. 1987;29-33.

  29. Bartolomei F, Gavaret M, Dhiver C. Isolated, chronic, epilepsia partialis continua in an HIV-infected patient. Arch Neurol. Jan 1999;56(1):111-4. [Medline].

  30. Ferrari S, Monaco S, Morbin M. HIV-associated PML presenting as epilepsia partialis continua. J Neurol Sci. Dec 11 1998;161(2):180-4. [Medline].

  31. Chalk CH, McManis PG, Cascino GD. Cryptococcal meningitis manifesting as epilepsia partialis continua of the abdomen. Mayo Clin Proc. Sep 1991;66(9):926-9. [Medline].

  32. Shavit YB, Graus F, Probst A, et al. Epilepsia partialis continua: a new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol. Feb 1999;45(2):255-8. [Medline].

  33. Komsuoglu SS, Liman O, Gurkan H. Epilepsia partialis continua following pertussis infection. Clin Electroencephalogr. Jan 1985;16(1):45-7. [Medline].

  34. Bansal SK, Sawhney IM, Chopra JS. Epilepsia partialis continua in Sjögren's syndrome. Epilepsia. Jul-Aug 1987;28(4):362-3. [Medline].

  35. Belopitova L, Bozhinova V, Khadzhibekov V. [A variant of the epilepsia partialis continua syndrome in a child with hypoplasia of the internal carotid artery]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1991;91(9):97-101 Russian. [Medline].

  36. Nobuhara K, Kagono Y, Kinoshita T. Two cases of epilepsia partialis continua associated with head trauma. Jpn J Psychiatry Neurol. Sep 1989;43(3):526-7. [Medline].

  37. Wroe SJ, Ellershaw JE, Whittaker JA, et al. Focal motor status epilepticus following treatment with azlocillin and cefotaxime. Med Toxicol. May-Jun 1987;2(3):233-4. [Medline].

  38. Shiozawa Z, Sasaki H, Ozaki Y. Epilepsia partialis continua following metrizamide cisternography. Ann Neurol. Oct 1981;10(4):400-1. [Medline].

  39. Tran, Thang X. Epilepsia partialis continua as a presenting manifestation of diabetic ketoacidosis. Ann Neurol. 1999;46(3):546.

  40. Chijioke CP, Mbah AU. Non-ketotic hyperglycaemia presenting as Epilepsia partialis continua. Cent Afr J Med. Dec 1996;42(12):349-51. [Medline].

  41. Uterga JM, Corredera C, Barrallo G, et al. [Epilepsia partialis continua: an unusual complication of liver insufficiency]. Rev Esp Enferm Dig. Oct 1995;87(10):756-7. [Medline].

  42. Spatt J, Goldenberg G, Mamoli B. Epilepsia partialis continua in multiple sclerosis. Lancet. Mar 11 1995;345(8950):658-9. [Medline].

  43. Gambardella A, Pasquinelli G, Cittadella R, Bono F, Oliveri RL, Valentino P, et al. Kufs' disease presenting as late-onset epilepsia partialis continua. Neurology. Oct 1998;51(4):1180-2. [Medline].

  44. Elia M, Musumeci SA, Ferri R, et al. Leigh syndrome and partial deficit of cytochrome c oxidase associated with epilepsia partialis continua. Brain Dev. May-Jun 1996;18(3):207-11. [Medline].

  45. Antozzi C, Franceschetti S, Filippini G, et al. Epilepsia partialis continua associated with NADH-coenzyme Q reductase deficiency. J Neurol Sci. Apr 1995;129(2):152-61. [Medline].

  46. Veggiotti P, Colamaria V, Dalla Bernardina B. Epilepsia partialis continua in a case of MELAS: clinical and neurophysiological study. Neurophysiol Clin. 1995;25(3):158-66. [Medline].

  47. Unverricht H. Die myoklonie. Leipzig: Franz Deuticke. 1891.

  48. Souques MA. Dissociation des paroxysmes convulsifs et des secousses inter paroxystique dans I E.P.C. et interpretation de cette dissociation. Rev Neurol. 1922;1:61-63.

  49. Grinker RR, Serota HSI. Myoclonic epilepsy. Arch Neurol Psychiatry. 1938;40:968-980.

  50. Dawson GD. Cerebral response to electrical stimulation of peripheral nerve in man. J Neurol Neurosurg Psychiatry. 1947;10:137-140.

  51. Dawson GD. Investigation on patient subject to myoclonic seizures after sensory stimulation. J Neurol Neurosurg Psychiatry. 1947;10:141-162.

  52. Kugelberg E, Widen L. Epilepsia Partialis Continua. Electroencephalogr Clin Neurophysiol. 1954;6:503-506.

  53. Bancaud J. Kojewnikow's syndrome (epilepsia partialis continua) in children. In: Rojer j, Bureau M, Dravet C, Dreifuss FE, Perret A, Wolf P, eds. Epileptic Syndromes in Infancy, Childhood, and Adolescence. 2nd ed. London: John Libbey;1992:363-79.

  54. Chauvel P, Trottier S, Vignal JP. Somatomotor seizures of frontal lobe origin. Adv Neurol. 1992;57:185-232. [Medline].

  55. Lamarche M, Chauvel P. Movement epilepsy in the monkey with an experimental motor focus. Electroencephalogr Clin Neurophysiol Suppl. 1978;(34):323-8. [Medline].

  56. Rothwell JC, Obeso JA, Marsden CD. On the significance of giant somatosensory evoked potentials in cortical myoclonus. J Neurol Neurosurg Psychiatry. Jan 1984;47(1):33-42. [Medline].

  57. Mazarati AM, Wasterlain CG. Blockers of NMDA receptor restore paired-pulse inhibition in the rat dentate gyrus lesioned by perforant path stimulation. Neurosci Lett. Oct 3 1997;234(2-3):135-8. [Medline].

  58. Echenne B, Rivier F, Roubertie A, et al. Successful felbamate treatment of epilepsia partialis continua in a case of hemimegalencephaly. Epilepsia. 1997;38 Supplement 3:36.

  59. Svein I, Johannessen Tomson, eds. Intractable Seizures and Epilepsies in Infancy and Early Childhood. Wrightson Biomedical Publishing Ltd;1995:19-20.

  60. Yoshida T, Tanaka M, Masuda T. [Epilepsia partialis continua with an epileptic focus demonstrated by PET and unique MRI findings: report of a case]. Rinsho Shinkeigaku. Sep 1995;35(9):1021-4. [Medline].

  61. Matthews R, Franceschi D, Xia W, Cabahug C, Schuman G, Bernstein R. Parietal lobe epileptic focus identified on SPECT-MRI fusion imaging in a case of epilepsia partialis continua. Clin Nucl Med. Dec 2006;31(12):826-8. [Medline].

  62. Burneo JG, Hamilton M, Vezina W, Parrent A. Utility of Ictal SPECT in the presurgical evaluation of Rasmussen's encephalitis. Can J Neurol Sci. Feb 2006;33(1):107-10. [Medline].

  63. Rogers SW, Andrews PI, Gahring LC, Whisenand T, Cauley K, Crain B, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science. Jul 29 1994;265(5172):648-51. [Medline].

  64. Barontini F, Maurri S, Amantini A. "Epilepsia partialis continua" due to multifocal encephalitis: favourable outcome after immunoglobulin treatment. Ital J Neurol Sci. Apr 1994;15(3):157-61. [Medline].

  65. Misawa S, Kuwabara S, Shibuya K, Mamada K, Hattori T. Low-frequency transcranial magnetic stimulation for epilepsia partialis continua due to cortical dysplasia. J Neurol Sci. Jul 15 2005;234(1-2):37-9. [Medline].

  66. Morales OG, Henry ME, Nobler MS. Electroconvulsive therapy and repetitive transcranial magnetic stimulation in children and adolescents: a review and report of two cases of epilepsia partialis continua. Child Adolesc Psychiatr Clin N Am. Jan 2005;14(1):193-210, viii-ix. [Medline].

  67. Rotenberg A, Depositario-Cabacar D, Bae EH, Harini C, Pascual-Leone A, Takeoka M. Transient suppression of seizures by repetitive transcranial magnetic stimulation in a case of Rasmussen's encephalitis. Epilepsy Behav. Jul 2008;13(1):260-2. [Medline].

  68. Brandt L, Saveland H, Ljunggren B, et al. Control of epilepsy partialis continuans with intravenous nimodipine. Report of two cases. J Neurosurg. Dec 1988;69(6):949-50. [Medline].

  69. McLachlan RS, Levin S, Blume WT. Treatment of Rasmussen's syndrome with ganciclovir. Neurology. Oct 1996;47(4):925-8. [Medline].

  70. Molyneux PD, Barker RA, Thom M, et al. Successful treatment of intractable epilepsia partialis continua with multiple subpial transections. J Neurol Neurosurg Psychiatry. Jul 1998;65(1):137-8. [Medline].

  71. Browner N, Azher SN, Jankovic J. Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis. Mov Disord. Sep 2006;21(9):1500-2. [Medline].

  72. Orlovskij SB. Ein Fall von epilepsia partialis continua. Neurol Zbl. 1896;15 (526):891-892.

  73. Takahashi Y, Mori H, Mishina M. Autoantibodies and cell-mediated immunity to NMDA-type GluRepsilon2 in patients with Rasmussen's encephalitis and chronic progressive epilepsia partialis continua. Epilepsia. 2005;46 S5:152-158. [Medline].

  74. Velasco M, Velasco F, Velasco AL. Effect of chronic electrical stimulation of the centromedian thalamic nuclei on various intractable seizure patterns: II. Psychological performance and background EEG activity. Epilepsia. Nov-Dec 1993;34(6):1065-74. [Medline].

Further Reading

Keywords

epilepsy, epilepsy treatment, epilepsy symptoms, simple partial status epilepticus, jacksonian status epilepticus, continuous localized myoclonia, somatomotor simple partial status epilepticus, EPC, myoclonus epilepsy

Contributor Information and Disclosures

Author

Claude G Wasterlain, MD, Chair, Department of Neurology, VA Greater Los Angeles Health Care System; Distinguished Professor and Vice-Chair, Department of Neurology, University of California, Los Angeles, David Geffen School of Medicine
Claude G Wasterlain, MD is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, American Federation for Medical Research, American Neurological Association, Royal Society of Medicine, and Society for Neuroscience
Disclosure: Nothing to disclose.

Coauthor(s)

Leo L Chen, MD, Staff Physician, Department of Neurology, University of California at Los Angeles
Leo L Chen, MD is a member of the following medical societies: American Academy of Family Physicians, American Academy of Neurology, American Medical Association, and American Medical Student Association/Foundation
Disclosure: Nothing to disclose.

Medical Editor

Edward B Bromfield, MD, Associate Professor of Neurology, Faculty Member, Division of Sleep Medicine, Harvard Medical School; Chief, Division of EEG, Epilepsy and Sleep Neurology, Consulting Neurologist, Brigham and Women's Hospital
Edward B Bromfield, MD is a member of the following medical societies: American Academy of Neurology, American Clinical Neurophysiology Society, American Epilepsy Society, American Neurological Association, and Massachusetts Medical Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Norberto Alvarez, MD, Assistant Professor, Department of Neurology, Harvard Medical School; Consulting Staff, Department of Neurology, Boston Children's Hospital
Norberto Alvarez, MD is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, and Child Neurology Society
Disclosure: Nothing to disclose.

CME Editor

Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital
Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital
Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.